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Sudden cardiac death in the young:  
cytokines and pathways
Abstract
Background and Purpose: The underlying mechanisms of sudden car-
diac death in terms of cytokines and pertinent signaling pathways have not 
been previously elaborated. The purpose of this paper is to clarify the cyto-
kines and signaling pathways involved in the mechanisms of sudden car-
diac death in the young.
Materials and Methods: Medical literature of sudden cardiac death in 
the young of recent decades were carefully collected as studying materials, 
and comprehensively reviewed and analyzed.
Results: Extrinsic and intrinsic apoptotic pathways, influenced by growth 
factor pathways, may render arrythmogenic cardiac disorders and ultimate-
ly lead to sudden cardiac death. Other cytokines probably involved in the 
mechanisms of sudden cardiac death in the young may include heme oxy-
genase-1 and the gaseous molecules (carbon monoxide and nitric oxide), 
insulin-like growth factor-1, gap junctional proteins and homeobox tran-
scription factor NKX2-5, which may be responsible for atrioventricular 
conduction impairments. Active therapeutic options for the pertinent ar-
rhythmias have significantly reduced the incidence of sudden cardiac death 
in the young. The apoptotic and growth factor signaling pathways are the 
two major ways leading to conduction system impairment and eventual 
sudden cardiac death.
Conclusions: The prophylactic antiarrhythmic agent, device therapies, 
or surgical operation could dramatically reduce sudden cardiac death inci-
dence. Good understanding of the mechanisms of the cytokine-related path-
ways is crucial for the treatment of the causative cardiac disorders respon-
sible for sudden cardiac death in the young. New agents including 
apoptotic blockers, heme metabolite homologues, and c-Src, PIK3 and 
NKX2-5 inhibitors, etc., are anticipated for the prevention of sudden car-
diac death in the near future.
INTRODUCTION
Sudden cardiac death (SCD) is an unexpected death from cardiac events, and occurs within one hour of onset of cardiac symptoms. 
In 25% of the cases, SCD occurred within 6 hours of physical activity 
(1). Preceding symptoms were reported in 35% of the cases prior to SCD. 
The symptoms can be circulatory (syncope, chest pain, dyspnea and 
palpitations), neurological (headache and visual disturbances), digestive, 
or institutional (e.g., recent febrile disease, usually a few days prior to 
SCD). It has been recognized that causes of SCD vary depending on 
age, gender, ethnicity and genetics (2). The incidence of SCD relies on 
population, of whom those in exercise are more likely vulnerable to SCD 
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(Table 1) (3-8). The incidence also varies on patients’ gen-
der, age and season: 2.3-fold higher in male than in fe-
male, increased with age, and highest in October and 
lowest in August (3). In a recent authoritative review, Ack-
erman et al. (9) made a summative assessment on the 
population-based estimates of SCD incidence in the 
young based on large medical centers from the world. The 
incidence differed depending on patient’s age, hospitals 
and regions, but showed an overall range of 0.7-10.1 per 
100,000 patient-years. However, the underlying mecha-
nisms of SCDs in terms of cytokines and pertinent signal-
ing pathways have not been previously elaborated. The 
purpose of this paper is to given a comprehensive review 
discussing the possible cytokine-related signaling path-
ways of SCDs in the young.
ETIOLOGIES
Berger (10) classified the etiological disorders for SCDs 
into structural or functional abnormalities, primary elec-
trical abnormalities, acquired conditions and postopera-
Figure 1. Distributions of causes of sudden cardiac death in the 
young athletes (11). HCM: hypertrophic cardiomyopathy.
Table 1. Incidence of sudden cardiac death
Population Incidence (per 
100,000 person-year)
Reference
General population 0.0092 (3)
Young individuals 2.28 (4)
0–2 years of age 2.1 (4)
3–13 years of age 0.61 (4)
14–24 years of age 1.44 (4)
25–35 years of age 4.40 (4)
Healthy men of exercise 5.56 (5)
Joggers 13.12 (6)
Basketball players 32.26 (7)
Young athletes (9-40 years) 0.11–33.33 (8)
Figure 2. Apoptotic signaling pathways (17). The extrinsic pathway is triggered by a binding of a ligand and a death receptor and the intrinsic 
pathway is activated by mitochondrial stress leading to cytochrome c release. By activating the initiator caspases and further the execution cas-
pases, the apoptosis is initiated. Bak: Bcl-2 homologous antagonist/killer; Bax: BCL-2-associated X protein; Bcl-2: B-cell lymphoma 2; Bcl-xL: 
B-cell lymphoma-extra large; BID: Bcl-2 interacting protein; FADD: Fas-associated death domain; FasL: Fas ligand; TNF: tumor necrosis factor.
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tive congenital heart disease. A representative review re-
spectively proposed that hypertrophic cardiomyopathy is 
the most common cause of SCD in young athletes (Fig. 
1) (11). Post-mortem analysis of cardiovascular pathology 
in SCD victims showed structurally normal heart in 27%, 
coronary artery disease in 21% and hypertrophic cardio-
myopathy in 15% (12). Consensus revealed hypertrophic 
cardiomyopathy the most common, congenital coronary 
artery anomalies, myocarditis, dilated cardiomyopathy, 
Marfan’s syndrome and arrhythmogenic right ventricular 
dysplasia (ARVD) the more common, and cardiac tumor, 
mitral valve prolapse, aortic valve stenosis, atherosclerotic 
coronary artery disease and long QT syndrome the lest 
common causes of SCDs in the young (13).
In infancy, the most common cause of death is con-
genital cardiac malformations. SCD may occur postop-
eratively in children with hypoplastic left heart syndrome 
between Norwood stage I and bidirectional Glenn pro-
cedures (14). The cause of SCD can be surgical technical 
problems, ventricular dysrhythmias, aspiration and al-
tered baroreceptor reflexes, and electrical instability re-
sulting from postoperative anatomical modifications. 
Majority of SCDs after repair of tetralogy of Fallot were 
due to ventricular arrhythmia, which could be screened 
by routine electrocardiogram (ECG) in whom SCDs oc-
cur later, and successful antiarrhythmic treatment could 
effectively prevent from SCDs (15).
Stenosis of the sinus node artery, which is frequent in 
patients younger than 40 years old as an important cause 
of SCD, is often associated with interstitial proliferation 
of the sinoatrial node. The etiologies of stenosis of the 
coronary orifice, an alternative common cause of SCD, 
include atheromatous plaque obstruction, syphilitic aor-
titis and congenital anomalies, with the latter one being 
less common than the previous two. Ion channelopathies 
represented by long QT, Brugada and Lev-Lenegre’s syn-
dromes with mutations of genes encoding sodium chan-
nels, as well as ventricular electrical storm characterized 
Table 2. A summary of potential cytokines and pathways involved in the mechanisms of sudden cardiac death in the young
Type of cytokines Participating factors Signaling pathways Function
Apoptotic regulator Tumor necrosis factor, anti-apoptotic 
proteins (Fas-L & Bcl-2) & pro- 
apoptotic proteins (Bak, Bax & Bad)
Apoptosis signaling pathways Triggering cardiac apoptosis
Heme oxygenase Heme oxygenase-1 p38 mitogen-activated protein kinase 
(MAPK), phosphatidylinositol-3 
kinase (PI3K)/Akt pathway, 
Jak-STAT pathway, toll-like receptor 
(TLR)-4 pathway




IGF-1 IGF-1 signaling pathway Promotion of the cell proliferation & 
differentiation & apoptosis inhibition
Cardiac gap  
junctions
Connexins 40, 43 & 45 PI3K/Akt-mediated pathway Electrical impulse propagation & 
coordinated contraction of the heart, 




Vascular endothelial growth factor Vascular endothelial growth 
factor signaling
Promotion of mitosis of the vascular 
endothelial cells & angiogenesis
NKX2-5 NKX2-5 Wnt signaling Cardiomyogenesis
HF-1b zinc finger 
protein
HF-1b Ras pathway A component of the endogenous 
HF-1b/myocyte enhancer factor 
(MEF) 2 binding activity in cardiac 
muscle cells
Heat shock proteins Heat shock proteins IGF-1 receptor signaling Suppression of apoptosis of 
cardiomyocytes, suppression of 
ubiquitination of IGF-1 receptor, 
augmentation of IGF-1 receptor 
signaling
Heat shock factor 1 Heat shock factor 1 Heat shock factor 1 signaling, IGF-1, 
transforming growth factor-b & cyclic 
guanosine monophosphate (cGMP) 
signaling
Protection against endotoxic shock
Calcineurin Calcineurin Calcineurin signaling Activation of the local production of 
nitric oxide by inducible nitric oxide 
synthase in myocardiocytes
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by critically malignant dysrhythmias due to extremely 
unstable electrical activities of the ventricle are also im-
portant causes of SCDs. In such patients, SCD has been 
evidenced histologically in the young victims by investi-
gating the pathology of conduction system. A congenital 
abnormality of the His bundle, such as loop formation 
and fragmentation or displacement found in the patho-
logical inspections was considered to be the cause of ar-
rhythmogenic sudden death (16).
CYTOKINES AND PATHWAYS
Several potential cytokines and pathways that impli-
cate in the pathogenesis of SCD in the young have been 
proposed. They are summarized in Table 2. Their poten-
tial roles for further targeting are described below.
Apoptotic regulators
Apoptosis is a complex process of a programmed cell 
death that involves collapse of cell, protein degradation 
and deoxyribonucleic acid fragmentation. Unlike necrosis 
where the cells swell and soon disintegrate, thereby evok-
ing an inflammatory response, apoptotic cells do not swell 
but actually shrink with extensive intracellular degenera-
tion. Apoptosis may inevitably lead to electric instability 
of the myocardium and cause SCD. A close correlation 
between apoptotic rate and left ventricular remodeling 
has been noted. Tumor necrosis factor (TNF) mediates 
cardiac apoptosis by way of both the extrinsic and intrin-
sic pathways (Fig. 2) (17). The Fas-mediated apoptotic 
pathway is a major extrinsic pathway triggering cardiac 
apoptosis as a result of interactions between the cell sur-
face death receptors (TNF receptor and Fas receptor) and 
extracellular ligands (TNF and Fas-L). The mitochon-
dria-dependent apoptotic pathway releases apoptosis-
regulating proteins from the intermembrane, exemplified 
by the B-cell lymphoma 2 (Bcl-2) family, such as Bcl-2 
homologous antagonist/killer (Bak), Bcl-2, Bcl-2-associ-
ated X protein (Bax) and Bcl-2-associated death promot-
er (Bad). Immunohistochemical studies on SCD victim 
heart revealed a direct proportion between Fas-L, caspase 
9 and Bax expression, indicating the role of apoptotic 
signal transduction mediated by Fas/Fas-L pathway in 
SCD (18). Experimental studies in transgenic mice isch-
emia-reperfusion model showed cardiac apoptosis could 
be inhibited by modification of apoptosis regulators and 
blockade of apoptosis executors. Moreover, extracellular 
signal-regulated kinases (ERK1/ERK2) and p38 mito-
gen-activated protein kinase (MAPK) pathways can be 
interacted with apoptosis pathways (19). The Janus kinase/
signal transducers and activators of transcription (JAK/
STAT) pathway was found to be closely related to inflam-
matory and apoptotic process. As a new downstream mo-
lecular target, it might regulate apoptosis and cell prolif-
eration induced by deoxynivalenol (DON) and T-2 toxin. 
In turn, JAK/STAT pathway might be the activated by 
the phosphorylation of MAPK, the release of proinflam-
matory cytokines from the cells through binding to the 
cytokine receptor and activating the kinase JAK. In ad-
dition, the JAK/STAT pathway might also be involved in 
the cardiotrophin-1, a member of the interleukin-6 fam-
ily, and pressure overload-induced cardiomyopathy (20).
Heme oxygenase (HO)
HO, isoformed by HO-1, HO-2 and HO-3, is respon-
sible for the physiological breakdown of heme into equi-
molar amounts of biliverdin, carbon monoxide (CO) and 
iron. HO-1 is ubiquitous and its messenger ribonucleic 
acid (mRNA) can be overexpressed by several folds in the 
presence of heme, other metalloporphyrins, transition 
metals and stress. HO-2 is present chiefly in the brain and 
testes and is virtually uninducible. HO-3 has very low 
enzyme activity. In isolated rat heart ischemia-reperfusion 
model, a significant reduction of HO-related CO produc-
tion was noted to be associated with reperfused ventricu-
lar fibrillation (VF), indicating the important arrhythmo-
genic role of the endogenous CO (21). Experimentally, 
zinc protoporphyrin IX (Zn-PPIX) (5 mM) treatment 
caused downregulation of HO-1 mRNA and a reduction 
of HO activity in VF hearts (22).
HO-1 overexpression inhibits proinflammatory cyto-
kines and chemokines under hypoxia, alleviates cardio-
myocyte apoptosis and regulating pathological left ven-
tricular remodeling (23). The anti-inf lammatory 
properties of HO-1 may rely on its ability to degrade heme 
and generate bilirubin, free iron and CO, and to reverse 
IL-18-mediated p38a MAPK and nuclear factor-kB ac-
tivation, phosphatase and tensin homolog (PTEN) induc-
tion, Akt suppression and endothelial cell death (24). 
HO-1 mRNA upregulation prevents from reperfused VF 
by promoting endogenous CO formation (21). Genetic 
missense mutation in cardiac potassium- and calcium-
channel proteins might be responsible for SCD from ven-
tricular arrhythmias.
The nuclear factor-erythroid (NF-E) 2-related factor 2 
(Nrf2) is a positive regulator of HO-1 gene induction (25). 
It is involved in protection against oxidant stress in car-
diovascular diseases, such as atherosclerosis, hypertension, 
heart failure and ischemia-reperfusion injury as well as 
aging. Alam et al. (25) have provided substantial evidence 
that overexpression of Nrf2M, a mutant of Nrf2, inhibits 
HO-1 mRNA accumulation in response to heme, zinc, 
cadmium and arsenic. Under conditions of Nrf2M over-
expression, HO-1 mRNA accumulation in response to 
heme, cadmium, zinc, arsenite and tert-butylhydroqui-
none was inhibited.
Insulin-like growth factor-1 (IGF-1)
IGF-1 displays multiple biological functions including 
promotion of the cell proliferation and differentiation and 
apoptosis inhibition by regulating gene expressions of the 
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myocytes. IGF-1 upregulates the phosphorylation levels 
of the Akt protein of the heart. LY294002, a specific in-
hibitor of the phosphatidylinositol 3-kinase (PI3K), not 
only reduces the level of Akt phosphorylation induced by 
IGF-1 itself, but also reverses IGF-1, promotes the func-
tional recovery of the cryopreserved heart, thereby playing 
an important anti-apoptotic role (26). Cardioprotective 
effects of IGF-1 against apoptosis are present through 
inhibition of apoptotic inducers, by upregulation of the 
renin-angiotensin system, or by downregulation of Krup-
pel-like factor 9, which further downregulates cyto-
chrome P450, a member of the cytochrome c family (27). 
IGF-1 partly recovers mitochondrial function of the my-
ocytes through downregulation of cytochrome c gene 
expression induced by hydrogen peroxide through down-
regulation of rKLF9 gene expressions. IGF-1 may exert 
dual effects, either protective or harmful, on cardio-
myoytes and on the vascular wall depending on whether 
the vascular endothelium is intact or impaired. Chisalita 
et al. (28) reported that the IGF-1 level was significantly 
higher in patients with heart failure or ischemic heart 
disease with angiotensin converting enzyme-inhibitor than 
those without (103.4 ± 39.7 μg/L vs. 84.4 ± 30.0 μg/L, 
p = 0.02). By contrast, Boquist et al. (29) offered a diver-
gent concept that fasting serum free IGF-1 correlated 
inversely with atherosclerosis-associated events based on 
a study on 96 healthy subjects.
Gap junctional proteins
The gap junctional channels are formed from connex-
ins (Cx’es), responsible for electrical impulse propagation 
and coordinated contraction of the heart. Altered gap 
junction distribution and function may lead to disturbed 
cardiac rhythmicity, including reentry. The human car-
diomyocytes express three different types of gap junction 
subunits: Cx43, Cx40 and Cx45 (30). Gap junction a-1 
protein, also known as Cx43, is a major gap junction pro-
tein maintaining normal electrical conduction in the 
heart. In Cx43-deficient mice, a 30-44% reduction of 
ventricular conduction velocity and prolongation of the 
QRS waves were observed (31). Cx gene deletion adverse-
ly affected the conduction system to a moderate degree as 
proved by the experiments in the heterozygous Cx40 and 
Cx43 knock-out mice. Cx43 conditional knockout mice 
with induced deletion of Cx43 in the heart exhibited re-
duced conduction velocity, increased dispersion of con-
duction, and enhanced electrical vulnerability on the 
ventricular level (32). Experimental studies revealed that 
Cx45 could be a substitute of Cx40 when the latter was 
deficient in the atrioventricular node, at least partly iden-
tifying the compensating properties of various Cx pro-
teins (33). In 156 probands with progressive familial heart 
block type I, a novel germ line heterozygous missense 
mutation in exon 2 of the Cx40 gene GJA5 was identified, 
whereas mutations were not found in connexin genes 
GJA1 (Cx43) or GJC1 (Cx45). Increased Cx43 mRNA 
and protein may lead to enhanced dye permeability and 
propagation of calcium (34).
Gap junction protein expression or functional altera-
tion may implicate an arrhythmogenic substrate in hyper-
trophic, ischemic, or dilated cardiomyopathies. Down-
regulation of Cx43 was observed in the ventricle of 
patients with hypertrophic, dilated and ischemic cardio-
myopathies. Increased heterogeneity of Cx43 was found 
in both patients with congestive heart failure and docu-
mented ventricular tachycardias and the heart failure 
mouse model that showed inducible polymorphic ven-
tricular tachycardia in the setting of heterogeneous Cx43 
loss. Cx43 is a plausible candidate gene for premature 
sudden death and a Cx43 mutation is a pathogenic sub-
strate for sudden infant death syndrome. Right ventricu-
lar endomyocardial biopsy in ARVD patients showed a 
significant reduced Cx40 mRNA and Cx45 mRNA ex-
pressions. Therefore, loss of gap junctions and shifted 
composition of gap junction channels of the conduction 
system might contribute to the development of ventricu-
lar arrhythmias in patients with ARVD (35).
Vascular endothelial growth factor 
(VEGF)
VEGF is a strong and specific cytokine that promotes 
mitosis of the vascular endothelial cells and angiogenesis. 
When subjected to hypoxia or ischemia, especially in the 
myocytes adjacent to the myocardial infarct area, the 
VEGF expressions are upregulated in the local tissues, 
probably due to the angiogenesis in that area (36). The 
patchy immunohistochemical positivity of hypoxia-in-
ducible factor-1a, erythropoietin and VEGF in cardio-
myocytes in the acute myocardial infarction and spo-
radic positivity in cardiomyocytes of SCD case without 
infarction indicate a proportion between the expressions 
and the structure damage of cardiomyocytes (37).
NKX2-5 and HF-1b
NKX2-5 and HF-1b implicate in conduction system 
development and disease. Several candidate molecules, 
including homeobox transcription factor NKX2-5, are 
related to SCD due to the resultant impaired conduction 
system, for example, in the context of gene mutations. 
HF-1b is a transcriptional factor preferentially expressed 
in the cardiac conduction system and ventricular myo-
cytes. HF-1b-deficient mice in associated with Cx40 re-
distribution predisposes to conduction system impair-
ment, subsequent malignant lethal arrhythmia and 
sudden death (38).
Heat shock proteins (HSPs) and 
calcineurin
HSPs confer protection against cardiovascular disease. 
Heat shock transcription factor (HSF)1 is one of the tran-
scription factors that regulate the expression of HSPs. 
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HSF1 is repressed by GSK-3b (Ser303), ERK (Ser307) 
and JNK (Ser363) under normal conditions; whereas, it 
is activated by hyperphosphorylation (Ser-230) upon ex-
posure to different stressors. HSFs including HO-1 pro-
vide significant protection against a variety of chemical 
and physical tissue damages associated with excessive pro-
duction of reactive oxygen species. In the heart of trans-
genic mice with HSF1 or inducible HSP70 overexpres-
sions, more resistance to ischemia-reperfusion injury was 
shown in compared with wildtype mice. In addition, 
HSPs may also protect against myocardial infarction and 
doxorubicin-induced cardiomyopathy (39). HSP90 was 
remarkably decreased in the tissues of hypertrophic car-
diomyopathy pigs of sudden death, but not in the tissues 
of non-hypertrophic cardiomyopathy or normal pigs. Cal-
cineurin, a protein phosphatase also known as protein 
phosphatase 3, and calcium-dependent serine-threonine 
phosphatase, activates the local production of NO by in-
ducible NO synthase in cardiac myocytes. Overexpres-
sion of calcineurin significantly contributes to sudden 
death, heart block, left ventricular dilation and impaired 
systolic performance of the ventricle (40).
MANAGEMENT
Screening investigations
In order to predict any potential SCDs, US Preventive 
Services Task Force proposed an analytic framework for 
screening including descriptive epidemiology and etiol-
ogy, screening methodology and optimal management. 
Of importance, ECG may reveal the causative cardiovas-
cular diseases responsible for SCD, such as cardiomyopa-
thies, channelopathies and cardiac conduction system 
diseases. Resting ECG serves as an adjunctive for disclos-
ing heart block of any degree or early repolarization syn-
drome; while stress ECG, for induced symptoms includ-
ing chest pain, ischemic ECG changes, conduction 
abnormalities and early repolarization during the exercise 
test; and echocardiogram, for cardiac structural or func-
tional abnormalities. Family evaluation and genetic test-
ing are also helpful in the early warning of SCDs (41).
Conservative treatment
Timely diagnosis of the underlying cardiovascular dis-
eases, prohibition of high intensity exercise, pharmaco-
therapy and other treatments help to prevent SCDs in the 
affected athletes. In the event of ventricular electrical 
storm, electric defibrillation and cardioversion should be 
performed as soon as possible for hemodynamic stabiliza-
tion. Current views support that b-blockers (metoprolol 
is preferred) is the drug of first choice, which is followed 
by amiodarone or sotalol, and a combination of both if 
necessary. As mitochondrial damage and Bcl-2-to-Bax 
balance play a central role in ischemia-dependent apop-
tosis while angiotensin II and b1-adrenergic-stimulation 
may be the major causes of receptor-mediated apoptosis, 
treatment with angiotensin-converting enzyme inhibitors 
and b-blockers could reduce myocardial apoptosis (42). 
Quinidine and isoproterenol are effective for the electrical 
storm of Brugada syndrome. In other genetic arrhyth-
mias, such as idiopathic long QT syndrome or short QT 
syndrome, b-blockers, quinidine and isoproterenol, etc., 
still have their places. c-Src inhibitor, such as 1-(1,1-di-
methylethyl)-1-(4-methylphenyl)-1H-pyrazolo(3,4-d)
pyri midin-4-amine (PP1), reduces c-Src and raises Cx43 
levels. Cx43 upregulation occurs primarily at the interca-
lated disks and correlates with gap junction functional 
improvement, and associated with a reduced risk of ven-
tricular tachycardia inducibility and SCD. The activation 
of renin-angiotensin system is associated with c-Src up-
regulation, Cx43 loss, reduced myocyte coupling and ar-
rhythmic sudden death (43).
Interventional therapy
Transcutaneous cardiac pacing may be considered in 
the patients with bradycardia and asystole. Radiofrequen-
cy ablation is indicated for abnormal electrical pathway 
arrhythmias including bundle-branch block and ven-
tricular tachycardia. However, implantable cardioverter 
defibrillator (ICD) is indicated in those with SCD and 
there are growing evidences showing the additional ben-
efit of radiofrequency ablation in treating ventricular ar-
rhythmia and electrical storm. Prophylactic cardioverter 
defibrillator therapy in patients at high risk of SCD has 
been attempted, and the annual SCD rate has been re-
duced dramatically (44).
Catheter ablation is a possible alternative to decrease 
the incidence of ICD therapy and is useful especially dur-
ing electrical storm after ICD implantation. Successful 
catheter ablation of focal VF and VF storm targeting 
Purkinje-like potentials in patients with non-ischemic 
dilated cardiomyopathy has been performed (45).
Cardiac surgery
Cardiac surgery can be a primary treatment for SCD. 
SCD in patients with anomalous origin of coronary artery 
is associated with the anatomical features in cluding ab-
normal coursing, acute angle take-off and ostial abnor-
malities. Surgical treatment is a definitive therapy. How-
ever, simple coronary artery bypass grafting is not 
recommended due to the potential hazards of coronary 
steal phenomenon and poor patency of the mammary 
arterial grafts. Nevertheless, modified maneuvers, such as 
coronary ostial reimplantation, impinged coronary seg-
ment unroofing and coronary stent de ployment, are ad-
vocated instead (46). Surgical treatment of ventricular 
arrhythmias includes excision of ventricular tachycardia 
foci and excision of left ventricular aneurysms. Aortic 
valve replacement and mitral valve repair or replacement, 
associated with improved outcome of patients with hemo-
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dynamically significant valvular stenosis and well-pre-
served ventricular function. Orthotopic heart transplan-
tation is indicated in patients with pending SCD and 
refractory heart failure with expected survival improve-
ment. Patients with long QT syndrome who do not re-
spond to b-blockers are candidates for ICD implantation 
or high thoracic left sympathectomy (44).
DISCUSSION
Ventricular arrhythmogenesis has been regarded as the 
main pathophysiological provocateur of SCD. The het-
erogeneous structural and functional conduction system 
impairments that disrupt the normal propagation of ac-
tion potentials through the ventricles initiated by certain 
cytokine-related pathways predisposes to the impulses 
around an anatomic barrier in ischemic or scarred myo-
cardium, or around a reentry in non-ischemic or structur-
ally normal myocardium. Three general mechanisms of 
arrhythmia in genetic conditions predisposing to SCD 
have been known as abnormal repolarization (long QT 
syndrome, short QT syndrome and Brugada syndrome), 
slow ventricular conduction (Brugada syndrome) and ab-
errant intracellular calcium homeostasis (catecholamin-
ergic polymorphic ventricular tachycardia). Molecular 
and genetic mechanisms interfering the NADH/NAD+ 
imbalance, protein kinase C activation and phosphoryla-
tion of a specific serine residue (Ser1503) on NaV1.5 and 
mutations of the ion channel genes have been illustrated. 
More broad research in this regard is warranted.
The autonomic nervous system serves as to modulate 
cardiac electrophysiology and arrhythmogenesis. In in-
herited arrhythmia disorders, sympathetic stimulation 
implicates in ventricular tachyarrhythmias and SCDs. In 
the animals susceptible to sudden death, modulation of 
the autonomic tone may increase cardiac vagal activity 
and reduce the risk for VF and SCDs (47).
Inflammatory arrhythmogenic mechanisms of proin-
flammatory cytokines have been received much attention. 
Inflammation links to various pathological processes, 
such as oxidative stress, apoptosis, fibrosis and arrhythmic 
substrate formation in the presence of endothelial dys-
function, platelet activation and coagulation cascade ac-
tivation. Increased TNF-a, interleukin-6 and interleu-
kin-4 levels was associated with more ventricular 
arrhythmias. Myocarditis, the actual inflammation of 
myocardium, represents a frequent cause of life-threaten-
ing ventricular arrhythmias and sudden death possibly 
through a modulation of ion channel function, mainly 
potassium and calcium channels in both viral and autoim-
mune myocarditis (48). Gap junctions are critical for 
maintaining synchronized impulse propagation and repo-
larization. Heterogeneous expression of the principal ven-
tricular gap junction protein Cx43 is associated with ac-
tion potential duration dispersion across the anterior 
ventricular wall (49). The Cx-containing channels are 
completely inactivated under inflammatory conditions, 
and the subsequent transmural electrophysiological het-
erogeneity of the left ventricle contributes to the underly-
ing arrhythmia susceptibility (49). Treatment with probu-
col by its antioxidant and/or antiinflammatory effects 
effectively attenuated left ventricular dysfunction and re-
modeling in tachycardia-induced heart failure model (50).
CONCLUSIONS
The mechanisms of SCD are complex, and all might 
ultimately be attributed to their arrthmogenic property. 
Apoptotic and growth factor signaling pathways are the 
two major ways that the cytokines follow, in a common 
sense, with the gaseous molecules CO and NO involved, 
leading to conduction system impairment and eventually 
SCDs. The prophylactic antiarrhythmic agent or device 
therapy could reduce SCD incidence dramatically. Good 
understanding of the mechanisms of these cytokine-re-
lated pathways is crucial for the prevention and treatment 
of the causative cardiac disorders. New agents including 
apoptotic blockers, heme metabolite homologues, and c-
Src, PIK3 and NKX2-5 inhibitors, etc., are highly antici-
pated in the prevention of SCDs in the near future.
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